Rapport Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $20,000 | $0 | $0 | $0 |
Gross Profit | 19,773 | -265 | -252 | |
EBITDA | -24,215 | -38,244 | -26,669 | -29,244 |
EBIT | -24,442 | -38,508 | -26,925 | -29,496 |
Net Income | -19,857 | -33,763 | -26,925 | -26,732 |
Net Change In Cash | 20,000 | 0 | 0 | 0 |
Free Cash Flow | -13,147 | -24,701 | -17,599 | -25,092 |
Cash | 78,056 | 52,645 | 251,359 | 55,067 |
Basic Shares | 47,236 | 46,978 | 37,931 | 35,444 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | -1,016 | -839 | -112 |
EBITDA | -124,082 | -77,468 | -34,664 |
EBIT | -125,099 | -78,307 | -34,776 |
Net Income | -111,483 | -78,307 | -34,786 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -88,089 | -67,233 | -28,817 |
Cash | 52,645 | 56,805 | 70,169 |
Basic Shares | 46,978 | 20,738 | 18,078 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.42 |
2025-12-31 | -$0.72 |
2025-09-30 | -$0.71 |
2025-06-30 | -$0.75 |